Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Br J Clin Pharmacol ; 90(6): 1503-1513, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38504437

ABSTRACT

AIMS: The aim of this study was to characterize the population pharmacokinetics of AZD8233, an antisense oligonucleotide (ASO) that targets the PCSK9 transcript to reduce hepatocyte PCSK9 protein production and plasma levels. AZD8233 utilizes generation 2.5 S-constrained ethyl motif (cET) chemistry and is conjugated to a triantennary N-acetylgalactosamine (GalNAc3) ligand for targeted hepatocyte uptake. METHODS: A non-linear mixed-effect modelling approach utilizing NONMEM software was applied to AZD8233 concentration-time data from 3416 samples in 219 participants from four phase 1-2 studies, one in healthy volunteers (NCT03593785) and three in patients with dyslipidaemia (NCT04155645, NCT04641299 and NCT04823611). RESULTS: The final model described the AZD8233 plasma concentration-time profile from four phase 1-2 studies in healthy volunteers or participants with dyslipidaemia, covering a dose range of 4 to 120 mg. The pharmacokinetics of AZD8233 were adequately described by a two-compartment model with first-order absorption. The supra-proportional increase in maximum plasma concentration (Cmax) across the observed dose range was described by non-linear Michaelis-Menten elimination (maximum elimination rate, 9.9 mg/h [12% relative standard error]; concentration yielding half-maximal elimination rate, 4.8 mg/L [18% relative standard error]). Body weight, sex, estimated glomerular filtration rate and disease status (healthy participant vs. patient with dyslipidaemia) were identified as factors affecting exposure to AZD8233. CONCLUSIONS: Covariate analysis showed body weight to be the main factor affecting exposure to AZD8233, which largely explained the higher Cmax observed in the Asian population relative to non-Asians.


Subject(s)
Dyslipidemias , Oligonucleotides, Antisense , Proprotein Convertase 9 , Humans , Male , Female , Middle Aged , Adult , Dyslipidemias/drug therapy , Dyslipidemias/genetics , Dyslipidemias/blood , Oligonucleotides, Antisense/pharmacokinetics , Oligonucleotides, Antisense/administration & dosage , Proprotein Convertase 9/genetics , Young Adult , Healthy Volunteers , Models, Biological , Aged , Dose-Response Relationship, Drug , Adolescent
2.
J Pharmacokinet Pharmacodyn ; 47(5): 421-430, 2020 10.
Article in English | MEDLINE | ID: mdl-32488575

ABSTRACT

Proper characterization of drug effects on Mycobacterium tuberculosis relies on the characterization of phenotypically resistant bacteria to correctly establish exposure-response relationships. The aim of this work was to evaluate the potential difference in phenotypic resistance in in vitro compared to murine in vivo models using CFU data alone or CFU together with most probable number (MPN) data following resuscitation with culture supernatant. Predictions of in vitro and in vivo phenotypic resistance i.e. persisters, using the Multistate Tuberculosis Pharmacometric (MTP) model framework was evaluated based on bacterial cultures grown with and without drug exposure using CFU alone or CFU plus MPN data. Phenotypic resistance and total bacterial number in in vitro natural growth observations, i.e. without drug, was well predicted by the MTP model using only CFU data. Capturing the murine in vivo total bacterial number and persisters during natural growth did however require re-estimation of model parameter using both the CFU and MPN observations implying that the ratio of persisters to total bacterial burden is different in vitro compared to murine in vivo. The evaluation of the in vitro rifampicin drug effect revealed that higher resolution in the persister drug effect was seen using CFU and MPN compared to CFU alone although drug effects on the other bacterial populations were well predicted using only CFU data. The ratio of persistent bacteria to total bacteria was predicted to be different between in vitro and murine in vivo. This difference could have implications for subsequent translational efforts in tuberculosis drug development.


Subject(s)
Antitubercular Agents/pharmacokinetics , Models, Biological , Mycobacterium tuberculosis/drug effects , Tuberculosis, Pulmonary/drug therapy , Animals , Antitubercular Agents/administration & dosage , Colony Count, Microbial , Disease Models, Animal , Drug Evaluation, Preclinical , Drug Resistance, Bacterial , Humans , Lung/microbiology , Lung/pathology , Mice , Microbial Sensitivity Tests , Mycobacterium tuberculosis/isolation & purification , Rifampin/administration & dosage , Rifampin/pharmacokinetics , Tuberculosis, Pulmonary/blood , Tuberculosis, Pulmonary/microbiology , Tuberculosis, Pulmonary/pathology
3.
J Antimicrob Chemother ; 73(2): 437-447, 2018 02 01.
Article in English | MEDLINE | ID: mdl-29136155

ABSTRACT

Background: Identification of pharmacodynamic interactions is not reasonable to carry out in a clinical setting for many reasons. The aim of this work was to develop a model-informed preclinical approach for prediction of clinical pharmacodynamic drug interactions in order to inform early anti-TB drug development. Methods: In vitro time-kill experiments were performed with Mycobacterium tuberculosis using rifampicin, isoniazid or ethambutol alone as well as in different combinations at clinically relevant concentrations. The multistate TB pharmacometric (MTP) model was used to characterize the natural growth and exposure-response relationships of each drug after mono exposure. Pharmacodynamic interactions during combination exposure were characterized by linking the MTP model to the general pharmacodynamic interaction (GPDI) model with successful separation of the potential effect on each drug's potency (EC50) by the combining drug(s). Results: All combinations showed pharmacodynamic interactions at cfu level, where all combinations, except isoniazid plus ethambutol, showed more effect (synergy) than any of the drugs alone. Using preclinical information, the MTP-GPDI modelling approach was shown to correctly predict clinically observed pharmacodynamic interactions, as deviations from expected additivity. Conclusions: With the ability to predict clinical pharmacodynamic interactions, using preclinical information, the MTP-GPDI model approach outlined in this study constitutes groundwork for model-informed input to the development of new and enhancement of existing anti-TB combination regimens.


Subject(s)
Antitubercular Agents/pharmacology , Drug Combinations , Drug Interactions , Mycobacterium tuberculosis/drug effects , Microbial Viability/drug effects , Models, Statistical
4.
J Antimicrob Chemother ; 71(4): 964-74, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26702921

ABSTRACT

OBJECTIVES: Mycobacterium tuberculosis can exist in different states in vitro, which can be denoted as fast multiplying, slow multiplying and non-multiplying. Characterizing the natural growth of M. tuberculosis could provide a framework for accurate characterization of drug effects on the different bacterial states. METHODS: The natural growth data of M. tuberculosis H37Rv used in this study consisted of viability defined as cfu versus time based on data from an in vitro hypoxia system. External validation of the natural growth model was conducted using data representing the rate of incorporation of radiolabelled methionine into proteins by the bacteria. Rifampicin time-kill curves from log-phase (0.25-16 mg/L) and stationary-phase (0.5-64 mg/L) cultures were used to assess the model's ability to describe drug effects by evaluating different linear and non-linear exposure-response relationships. RESULTS: The final pharmacometric model consisted of a three-compartment differential equation system representing fast-, slow- and non-multiplying bacteria. Model predictions correlated well with the external data (R(2) = 0.98). The rifampicin effects on log-phase and stationary-phase cultures were separately and simultaneously described by including the drug effect on the different bacterial states. The predicted reduction in log10 cfu after 14 days and at 0.5 mg/L was 2.2 and 0.8 in the log-phase and stationary-phase systems, respectively. CONCLUSIONS: The model provides predictions of the change in bacterial numbers for the different bacterial states with and without drug effect and could thus be used as a framework for studying anti-tubercular drug effects in vitro.


Subject(s)
Antitubercular Agents/pharmacology , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/growth & development , Tuberculosis/microbiology , Algorithms , Bacterial Proteins/biosynthesis , Colony Count, Microbial , Dose-Response Relationship, Drug , Humans , Methionine/metabolism , Microbial Sensitivity Tests , Models, Biological , Predictive Value of Tests , Radiopharmaceuticals/metabolism , Rifampin/pharmacology
5.
Eur J Clin Pharmacol ; 71(3): 313-9, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25620089

ABSTRACT

PURPOSE: The purpose of the study was to develop a drug-unspecific approach to pharmacometric modeling for predicting the rate and extent of distribution from plasma to epithelial lining fluid (ELF) and alveolar cells (AC) for data emanating from studies involving bronchoalveolar lavage (BAL) sampling, using rifampicin (RIF) as an example. METHODS: Data consisting of RIF plasma concentrations sampled at approximately 2 and 4 h postdose and ELF and AC concentrations quantified from one BAL sample, taken at approximately 4 h postdose, in 40 adult subjects without tuberculosis was used as an example for model development. RESULTS: This study emphasized the usage of drug-specific plasma pharmacokinetics (PK) for a correct characterization of plasma to pulmonary distribution. As such, RIF PK was described using absorption transit compartments and a one compartment distribution model coupled with an enzyme turn-over model. The ELF and AC distribution model consisted of characterization of the rate of distribution of drug from plasma to ELF and AC by two distribution rate constant, k ELF and k AC, respectively. The extent of distribution to ELF and AC was described by unbound ELF/plasma concentration ratio (R ELF/unbound-plasma) and unbound AC/plasma concentration ratio (R AC/unbound-plasma) which typical values were predicted to be 1.28 and 5.5, respectively. CONCLUSIONS: The model together with a drug-specific plasma PK description provides a tool for handling data from both single and multiple BAL sampling designs and directly predicts the rate and extent of distribution from plasma to ELF and AC. The model can be further used to investigate design aspects of optimized BAL studies.


Subject(s)
Bronchoalveolar Lavage Fluid/chemistry , Pulmonary Alveoli/cytology , Rifampin/blood , Rifampin/pharmacokinetics , Female , Humans , Male , Models, Biological , Rifampin/analysis
6.
J Pharmacokinet Pharmacodyn ; 42(6): 699-708, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26316105

ABSTRACT

Bronchoalveolar lavage (BAL) is a pulmonary sampling technique for characterization of drug concentrations in epithelial lining fluid and alveolar cells. Two hypothetical drugs with different pulmonary distribution rates (fast and slow) were considered. An optimized BAL sampling design was generated assuming no previous information regarding the pulmonary distribution (rate and extent) and with a maximum of two samples per subject. Simulations were performed to evaluate the impact of the number of samples per subject (1 or 2) and the sample size on the relative bias and relative root mean square error of the parameter estimates (rate and extent of pulmonary distribution). The optimized BAL sampling design depends on a characterized plasma concentration time profile, a population plasma pharmacokinetic model, the limit of quantification (LOQ) of the BAL method and involves only two BAL sample time points, one early and one late. The early sample should be taken as early as possible, where concentrations in the BAL fluid ≥ LOQ. The second sample should be taken at a time point in the declining part of the plasma curve, where the plasma concentration is equivalent to the plasma concentration in the early sample. Using a previously described general pulmonary distribution model linked to a plasma population pharmacokinetic model, simulated data using the final BAL sampling design enabled characterization of both the rate and extent of pulmonary distribution. The optimized BAL sampling design enables characterization of both the rate and extent of the pulmonary distribution for both fast and slowly equilibrating drugs.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Bronchoalveolar Lavage Fluid/chemistry , Bronchoalveolar Lavage/methods , Lung/metabolism , Models, Biological , Models, Statistical , Specimen Handling/methods , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Computer Simulation , Drug Administration Routes , Drug Administration Schedule , Epithelial Cells/metabolism , Humans , Pulmonary Alveoli/metabolism , Tissue Distribution
7.
Sci Rep ; 10(1): 15537, 2020 09 23.
Article in English | MEDLINE | ID: mdl-32968142

ABSTRACT

This study aimed to investigate the number of persistent bacteria in sputum from tuberculosis patients compared to in vitro and to suggest a model-based approach for accounting for the potential difference. Sputum smear positive patients (n = 25) provided sputum samples prior to onset of chemotherapy. The number of cells detected by conventional agar colony forming unit (CFU) and most probable number (MPN) with Rpf supplementation were quantified. Persistent bacteria was assumed to be the difference between MPNrpf and CFU. The difference in persistent bacteria between in vitro and human sputum prior to chemotherapy was quantified using different model-based approaches. The persistent bacteria in sputum was 17% of the in vitro levels, suggesting a difference in phenotypic resistance, whereas no difference was found for multiplying bacterial subpopulations. Clinical trial simulations showed that the predicted time to 2 log fall in MPNrpf in a Phase 2a setting using in vitro pre-clinical efficacy information, would be almost 3 days longer if drug response was predicted ignoring the difference in phenotypic resistance. The discovered phenotypic differences between in vitro and humans prior to chemotherapy could have implications on translational efforts but can be accounted for using a model-based approach for translating in vitro to human drug response.


Subject(s)
Mycobacterium tuberculosis/drug effects , Sputum/microbiology , Tuberculosis, Pulmonary/microbiology , Antitubercular Agents/therapeutic use , Drug Resistance, Bacterial , Humans , Models, Biological , Mycobacterium tuberculosis/growth & development , Stem Cells , Tuberculosis, Pulmonary/drug therapy
8.
Clin Pharmacol Ther ; 104(6): 1208-1218, 2018 12.
Article in English | MEDLINE | ID: mdl-29700814

ABSTRACT

A crucial step for accelerating tuberculosis drug development is bridging the gap between preclinical and clinical trials. In this study, we developed a preclinical model-informed translational approach to predict drug effects across preclinical systems and early clinical trials using the in vitro-based Multistate Tuberculosis Pharmacometric (MTP) model using rifampicin as an example. The MTP model predicted rifampicin biomarker response observed in 1) a hollow-fiber infection model, 2) a murine study to determine pharmacokinetic/pharmacodynamic indices, and 3) several clinical phase IIa early bactericidal activity (EBA) studies. In addition, we predicted rifampicin biomarker response at high doses of up to 50 mg/kg, leading to an increased median EBA0-2 days (90% prediction interval) of 0.513 log CFU/mL/day (0.310; 0.701) compared to the standard dose of 10 mg/kg of 0.181 log/CFU/mL/day (0.076; 0.483). These results suggest that the translational approach could assist in the selection of drugs and doses in early-phase clinical tuberculosis trials.


Subject(s)
Antibiotics, Antitubercular/administration & dosage , Computer Simulation , Models, Biological , Mycobacterium tuberculosis/drug effects , Rifampin/administration & dosage , Translational Research, Biomedical/methods , Tuberculosis, Pulmonary/drug therapy , Animals , Antibiotics, Antitubercular/adverse effects , Antibiotics, Antitubercular/pharmacokinetics , Bacterial Load , Clinical Trials, Phase II as Topic , Disease Models, Animal , Dose-Response Relationship, Drug , Humans , Mice , Microbial Sensitivity Tests , Mycobacterium tuberculosis/growth & development , Rifampin/adverse effects , Rifampin/pharmacokinetics , Treatment Outcome , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/microbiology
9.
Nat Commun ; 8(1): 2129, 2017 12 14.
Article in English | MEDLINE | ID: mdl-29242552

ABSTRACT

Assessment of pharmacodynamic (PD) drug interactions is a cornerstone of the development of combination drug therapies. To guide this venture, we derive a general pharmacodynamic interaction (GPDI) model for ≥2 interacting drugs that is compatible with common additivity criteria. We propose a PD interaction to be quantifiable as multidirectional shifts in drug efficacy or potency and explicate the drugs' role as victim, perpetrator or even both at the same time. We evaluate the GPDI model against conventional approaches in a data set of 200 combination experiments in Saccharomyces cerevisiae: 22% interact additively, a minority of the interactions (11%) are bidirectional antagonistic or synergistic, whereas the majority (67%) are monodirectional, i.e., asymmetric with distinct perpetrators and victims, which is not classifiable by conventional methods. The GPDI model excellently reflects the observed interaction data, and hence represents an attractive approach for quantitative assessment of novel combination therapies along the drug development process.


Subject(s)
Algorithms , Computer Simulation , Models, Biological , Saccharomyces cerevisiae/drug effects , Drug Antagonism , Drug Interactions , Drug Synergism , Drug Therapy, Combination , Humans , Saccharomyces cerevisiae/growth & development
10.
AAPS J ; 13(4): 598-605, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21913053

ABSTRACT

The objective of this work was to examine the atazanavir-bilirubin relationship using a population-based approach and to assess the possible application of bilirubin as a readily available marker of atazanavir exposure. A model of atazanavir exposure and its concentration-dependent effect on bilirubin levels was developed based on 200 atazanavir and 361 bilirubin samples from 82 patients receiving atazanavir in the NORTHIV trial. The pharmacokinetics was adequately described by a one-compartment model with first-order absorption and lag-time. The maximum inhibition of bilirubin elimination rate constant (I(max)) was estimated at 91% (95% CI, 87-94) and the atazanavir concentration resulting in half of I(max) (IC50) was 0.30 µmol/L (95% CI, 0.24-0.37). At an atazanavir/ritonavir dose of 300/100 mg given once daily, the bilirubin half-life was on average increased from 1.6 to 8.1 h. A nomogram, which can be used to indicate suboptimal atazanavir exposure and non-adherence, was constructed based on model simulations.


Subject(s)
Bilirubin/blood , Biomarkers/blood , HIV Infections/drug therapy , HIV Protease Inhibitors/pharmacokinetics , Oligopeptides/pharmacokinetics , Pyridines/pharmacokinetics , Atazanavir Sulfate , HIV Infections/blood , HIV Protease Inhibitors/therapeutic use , Humans , Oligopeptides/therapeutic use , Pyridines/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL